Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Champions Oncology Reports Results for the Second Quarter Ended October 31, 2014

PR Newswire December 12, 2014

Oncotype DX® DCIS Score(TM) Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer

PR Newswire December 12, 2014

Research and Markets: Mexico Gynecological Devices Market Outlook to 2020: Key players covered include Bayer, Hologic, Boston Scientific, Microsulis, Cook and Merit

Business Wire December 12, 2014

Research and Markets: Mexico Non-Vascular Stents Market Outlook to 2020: Key players covered include Boston Scientific, Taewoong, Merit, Cook, PNN, Teleflex and C.R. Bard

Business Wire December 12, 2014

HOT TOPIC: Ebola Outbreak

Business Wire December 12, 2014

Research and Markets: Italy Biopsy Devices Market Outlook to 2020: Key players covered include C.R. Bard, Cook, CareFusion and Hologic

Business Wire December 12, 2014

Research and Markets: Spain Non-Vascular Stents Market Outlook to 2020: Key players covered include Boston Scientific, Taewoong, Merit, Cook, PNN, Teleflex and C.R. Bard

Business Wire December 12, 2014

Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium

GlobeNewswire December 12, 2014

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

PR Newswire December 12, 2014

Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer

Marketwired December 12, 2014

Research and Markets: Italy Gynecological Devices Market Outlook to 2020: Key players covered include Bayer, Hologic, Boston Scientific, Microsulis, Cook and Merit

Business Wire December 12, 2014

Research and Markets: Italy Non-Vascular Stents Market Outlook to 2020: Key players covered include Boston Scientific, Taewoong, Merit, Cook, PNN, Teleflex and C.R. Bard

Business Wire December 12, 2014

Advaxis's Cancer Immunotherapies Featured on FOX News

GlobeNewswire December 12, 2014

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

Business Wire December 12, 2014

Research and Markets: Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

Business Wire December 12, 2014

BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform

Business Wire December 12, 2014

Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs"

Business Wire December 12, 2014

Safety and efficacy benefit of (Pr)Jakavi(TM) shown in clinical trial of over 1,000 patients with myelofibrosis

Canada NewsWire December 12, 2014

Research and Markets: Research & Reviews: Journal of Microbiology & Virology

Business Wire December 12, 2014

TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan

PR Newswire December 12, 2014